Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$152.4M
46M shares
52-week range
$3.21 – $6.61
3% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
www.korumedical.comNo one on the platform currently holds KRMD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 45,900 | $198.3K |
No one on the platform has traded KRMD yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$KRMD This is a very interesting company trading at a remarkably low valuation. KRMD has demonstrated that its growth is becoming both profitable and sustainable: core revenue grew 23%, international revenue surged 59%, gross margin reached 65.1%, and both adjusted EBITDA and net income turned positive. Management also indicated that the expected moderation in international growth is largely a timing issue rather than weakening demand, while the oncology strategy is being redirected toward larger-volume opportunities after withdrawing Phesgo.
View on StockTwits ↗$KRMD KORU Medical Systems Inc (KRMD) carries a consensus Buy (or Moderate/Strong Buy) rating from Wall Street analysts. The average 12-month price target sits around $6.80 to $7.25, presenting notable upside potential from its recent trading price near $4.11 to $4.28
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-8-5-repro-med-systems-inc-stock/ $KRMD KORU Medical Systems Earnings Transcript
View on StockTwits ↗$KRMD Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.01 • Reported revenue of $12.05M up 18.15% YoY
View on StockTwits ↗$KRMD Develops and markets the Freedom Syringe Infusion System, designed for subcutaneous infusion therapies. Its niche focus gives it an opportunity to become a preferred device platform for certain specialty drugs.´!!
View on StockTwits ↗@fepangg1669 @kurtb1969 Also check $KRMD chart after Horton became a stakeholder and appointed Mr. Manko as a director in 2016. It is of course apples to oranges but still informative.
View on StockTwits ↗$KRMD At roughly a $180 million market cap, KRMD remains relatively undiscovered by institutional investors. Real revenue growth (22%) Improving profitability No immediate financing concerns Multiple potential commercial catalysts Significant analyst upside targets
View on StockTwits ↗$KRMD CEO purchased 1,191 shares at $3.92 for a total of $4,669. Tharby Linda M now owns 620,622 shares. https://ceo-buys.com
View on StockTwits ↗$KRMD CEO purchased 1,191 shares at $1191.00 for a total of $1,418,481. Tharby Linda M now owns 620,622 shares. https://ceo-buys.com
View on StockTwits ↗$KRMD CEO purchased additional shares: https://www.sec.gov/Archives/edgar/data/704440/000116169726000122/0001161697-26-000122-index.htm
View on StockTwits ↗$MYO Regarding today's appointment of Joseph Manko, check Koru Medical Systems $KRMD history after Horton investment.
View on StockTwits ↗$XTNT $FBIO $KRMD All attempting to do great things
View on StockTwits ↗$KRMD solid execution shown Q1 w new CEO likely to accelerate push into non IG. Underappreciated IMO how large the opportunity is in infusion centers, especially oncology drugs, which can be maddening for nurses to push manually multiple patients. Valuation very modest
View on StockTwits ↗$KRMD Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.02 up 33.33% YoY • Reported revenue of $11.76M up 22.10% YoY • Koru Medical Systems amended its loan agreement, extending the $5,000,000 revolver maturity to March 30, 2028, and the $5,000,000 term loan maturity to December 1, 2029, while lowering the interest rate floor to 5.50%.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.